Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 17, 2009

Synta Obtains $10M from GSK under Cancer Deal

  • Synta Pharmaceuticals achieved an operational milestone triggering a $10 million payment from GlaxoSmithKline (GSK) under its collaboration for elesclomol. The drug is currently being studied in combination with paclitaxel in a Phase III trial in metastatic melanoma.

    In October 2007, Synta and GSK inked a deal covering elesclomol that was worth $965 million. Synta has earned a total of $130 million to date, including $80 million up front and $25 million for milestones achieved in October and  $15 million for milestones achieved in December 2008.

    The company is eligible for a total of $585 million in precommercial milestone payments: $150 related to development in melanoma and the remainder related to other cancer indications.  Synta is also eligible to $300 million in sales milestones, 40-50% share of operating profits in the U.S., and double-digit royalties on ex-U.S. sales.

    Elesclomol is an investigational first-in-class oxidative stress inducer that triggers apoptosis in cancer cells. Enrollment for the Phase III study was completed earlier this month.

     

    ---

    To comment on this story, go to BLOGbiotech.



Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »